Trial Profile

Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 2302025A (Primary)
Indications Malignant melanoma
Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
Acronyms PRAME-AS15-MEL001
Sponsors GlaxoSmithKline; GSK

Most Recent Events

02 May 2019 This trial was completed in France (end date:19 Dec 2016).
02 Mar 2017 Status changed from active, no longer recruiting to completed.
04 Feb 2017 This trial was completed in Czech Republic (end date:19 Dec 2016).

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com